Erratum to “Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53” [Toxicol. Appl. Pharmacol. 232(1) (2008) 86–98] (S0041008X08002512) (10.1016/j.taap.2008.06.006));Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53

Toxicology and Applied Pharmacology

Volumn 232, Issue 1, 2008, Pages 86-98

  Simões, Maria L ^a   Hockley, Sarah L ^a   Schwerdtle, Tanja ^b   Gamboa da Costa, Gonçalo ^a   Schmeiser, Heinz H ^c   Phillips, David H ^a   Arlt, Volker M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Aristolochic acid; Gene expression; Microarray; TP53; Urothelial cancer

Indexed keywords

ARISTOLOCHIC ACID; CARCINOGEN; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CAV1 GENE; CCNG1 GENE; CDKN1A GENE; CELL CYCLE; CONTROLLED STUDY; DNA ADDUCT; DNA REPLICATION; DOWN REGULATION; EGR1 GENE; ENDOCYTOSIS; ENZYME ACTIVITY; FOS GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INSIG1 GENE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; LCN2 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PHENOTYPE; PROTEIN EXPRESSION; RAB5A GENE; SIGNAL TRANSDUCTION; TP53 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; UROGENITAL TRACT TUMOR;

EID: 51549086000     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2018.02.010     Document Type: Erratum

References (95)

1. Amundson S.A., Do K.T., Vinikoor L., Koch-Paiz C.A., Bittner M.L., Trent J.M., Meltzer P., and Fornace Jr. A.J. Stress-specific signatures: expression profiling of p53 wild-type and -null human cells. Oncogene 24 (2005) 4572-4579
2. Arlt V.M., Wiessler M., and Schmeiser H.H. Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. Carcinogenesis 21 (2000) 235-242
3. Arlt V.M., Pfohl-Leszkowicz A., Cosyns J., and Schmeiser H.H. Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat. Res. 494 (2001) 143-150
4. Arlt V.M., Schmeiser H.H., and Pfeifer G.P. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22 (2001) 133-140
5. Arlt V.M., Stiborova M., and Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002) 265-277
6. Arlt V.M., Alunni-Perret V., Quatrehomme G., Ohayon P., Albano L., Gaid H., Michiels J.F., Meyrier A., Cassuto E., Wiessler M., Schmeiser H.H., and Cosyns J.P. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. Int. J. Cancer 111 (2004) 977-980
7. Arlt V.M., Stiborova M., Henderson C.J., Osborne M.R., Bieler C.A., Frei E., Martinek V., Sopko B., Wolf C.R., Schmeiser H.H., and Phillips D.H. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 65 (2005) 2644-2652
8. Arlt V.M., Glatt H., Gamboa da Costa G., Reynisson J., Takamura-Enya T., and Phillips D.H. Mutagenicity and DNA adduct formation by the urban air pollutant 2-nitrobenzanthrone. Toxicol. Sci. 98 (2007) 445-457
9. Arlt V.M., Stiborova M., Brocke J.V., Simoes M.L., Lord G.M., Nortier J.L., Hollstein M., Phillips D.H., and Schmeiser H.H. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28 (2007) 2253-2261
10. Atencio I.A., Ramachandra M., Shabram P., and Demers G.W. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ. 11 (2000) 247-253
11. Balachandran P., Wei F., Lin R.C., Khan I.A., and Pasco D.S. Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. Kid. Inter. 67 (2005) 1797-1805
12. Baron V., Adamson E.D., Calogero A., Ragona G., and Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 13 (2006) 115-124
13. Bieler C.A., Stiborova M., Wiessler M., Cosyns J.P., van Ypersele de Strihou C., and Schmeiser H.H. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18 (1997) 1063-1067
14. Boiteux S., Gajewski E., Laval J., and Dizdaroglu M. Substrate specificity of the Escherichia coli Fpg protein (formamidopyrimidine-DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitization. Biochemistry 31 (1992) 106-110
15. Bratt T. Lipocalins and cancer. Biochim. Biophys. Acta 1482 (2000) 318-326
16. Broschard T.H., Wiessler M., von der Lieth C.W., and Schmeiser H.H. Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis 15 (1994) 2331-2340
17. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
18. Carver L.A., and Schnitzer J.E. Caveolae: mining little caves for new cancer targets. Nature Rev. 3 (2003) 571-581
19. Chang H.R., Lian J.D., Lo C.W., Huang H.P., and Wang C.J. Aristolochic acid-induced cell cycle G1 arrest in human urothelium SV-HUC-1 cells. Food Chem. Toxicol. 45 (2007) 396-402
20. Chatterjee A., Mambo E., Osada M., Upadhyay S., and Sidransky D. The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity. Faseb J. 20 (2006) 112-114
21. Chen T., Guo L., Zhang L., Shi L., Fang H., Sun Y., Fuscoe J.C., and Mei N. Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. BMC Bioinformatics 7 Suppl 2 (2006) S20
22. Christensen E.I., Devuyst O., Dom G., Nielsen R., Van der Smissen P., Verroust P., Leruth M., Guggino W.B., and Courtoy P.J. Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc. Natl. Acad. Sci. U S A 100 (2003) 8472-8477
23. Cosyns J.P. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf. 26 (2003) 33-48
24. Cosyns J.P., Jadoul M., Squifflet J.P., Wese F.X., and van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33 (1999) 1011-1017
25. Del Bello B., Moretti D., Gamberucci A., and Maellaro E. Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status. Oncogene 26 (2007) 2717-2726
26. Dennis Jr. G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., and Lempicki R.A. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4 (2003) P3
27. Dipple A., Khan Q.A., Page J.E., Ponten I., and Szeliga J. DNA reactions, mutagenic action and stealth properties of polycyclic aromatic hydrocarbon carcinogens (review). Int. J. Oncol. 14 (1999) 103-111
28. Dornetshuber R., Heffeter P., Kamyar M.R., Peterbauer T., Berger W., and Lemmens-Gruber R. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chem. Res. Toxicol. 20 (2007) 465-473
29. el-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54 (1994) 1169-1174
30. Feldmeyer N., Schmeiser H.H., Muehlbauer K.R., Belharazem D., Knyazev Y., Nedelko T., and Hollstein M. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat. Res. 608 (2006) 163-168
31. Gauger M.A., and Sancar A. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 65 (2005) 6828-6834
32. Gold L.S., and Slone T.H. Aristolochic acid, an herbal carcinogen, sold on the Web after FDA alert. New Engl. J. Med. 349 (2003) 1576-1577
33. Grimm M.O., Jurgens B., Schulz W.A., Decken K., Makri D., and Schmitz-Drager B.J. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol. Res. 23 (1995) 293-300
34. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelic M., and Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U S A 104 (2007) 12129-12134
35. Guo L., Lobenhofer E.K., Wang C., Shippy R., Harris S.C., Zhang L., Mei N., Chen T., Herman D., Goodsaid F.M., Hurban P., Phillips K.L., Xu J., Deng X., Sun Y.A., Tong W., Dragan Y.P., and Shi L. Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat. Biotech. 24 (2006) 1162-1169
36. Habuchi T., Kinoshita H., Yamada H., Kakehi Y., Ogawa O., Wu W.J., Takahashi R., Sugiyama T., and Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst. 86 (1994) 1331-1335
37. Hartwig A., Dally H., and Schlepegrell R. Sensitive analysis of oxidative DNA damage in mammalian cells: use of the bacterial Fpg protein in combination with alkaline unwinding. Toxicol. Lett. 88 (1996) 85-90
38. Hockley S.L., Arlt V.M., Brewer D., Giddings I., and Phillips D.H. Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2. BMC Genomics 7 (2006) 260
39. Hockley S.L., Arlt V.M., Brewer D., Te Poele R., Workman P., Giddings I., and Phillips D.H. AHR- and DNA-Damage-Mediated Gene Expression Responses Induced by Benzo(a)pyrene in Human Cell Lines. Chem. Res. Toxicol. 20 (2007) 1797-1810
40. Hockley S.L., Arlt V.M., Jahnke G., Hartwig A., Giddings I., and Phillips D.H. Identification through microarray gene expression analysis of cellular responses to benzo(a)pyrene and its diol-epoxide that are dependent or independent of p53. Carcinogenesis 29 (2008) 202-210
41. Hosack D.A., Dennis Jr. G., Sherman B.T., Lane H.C., and Lempicki R.A. Identifying biological themes within lists of genes with EASE. Genome Biol. 4 (2003) R70
42. Hsin Y.H., Cheng C.H., Tzen J.T., Wu M.J., Shu K.H., and Chen H.C. Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells. Apoptosis 11 (2006) 2167-2177
43. Hussain S.P., Hollstein M.H., and Harris C.C. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Annals New York Acad. Sci. 919 (2000) 79-85
44. Hvidberg V., Jacobsen C., Strong R.K., Cowland J.B., Moestrup S.K., and Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 579 (2005) 773-777
45. IARC. Some tratitional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risk. Hum. (2002) 82
46. Kabanda A., Jadoul M., Lauwerys R., Bernard A., and van Ypersele de Strihou C. Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int. 48 (1995) 1571-1576
47. Kamai T., Tsujii T., Arai K., Takagi K., Asami H., Ito Y., and Oshima H. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9 (2003) 2632-2641
48. Khan Q.A., and Dipple A. Diverse chemical carcinogens fail to induce G(1) arrest in MCF-7 cells. Carcinogenesis 21 (2000) 1611-1618
49. Khan Q.A., Vousden K.H., and Dipple A. Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1). Carcinogenesis 18 (1997) 2313-2318
50. Khan Q.A., Vousden K.H., and Dipple A. Lack of p53-mediated G1 arrest in response to an environmental carcinogen. Oncology 57 (1999) 258-264
51. Krones-Herzig A., Mittal S., Yule K., Liang H., English C., Urcis R., Soni T., Adamson E.D., and Mercola D. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res. 65 (2005) 5133-5143
52. Lanzetti L., Di Fiore P.P., and Scita G. Pathways linking endocytosis and actin cytoskeleton in mammalian cells. Exp. Cell Res. 271 (2001) 45-56
53. Lebeau C., Arlt V.M., Schmeiser H.H., Boom A., Verroust P.J., Devuyst O., and Beauwens R. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int. 60 (2001) 1332-1342
54. Lebeau C., Debelle F.D., Arlt V.M., Pozdzik A., De Prez E.G., Phillips D.H., Deschodt-Lanckman M.M., Vanherweghem J.L., and Nortier J.L. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol. Dial. Transplant 20 (2005) 2321-2332
55. Lee J.N., and Ye J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J. Biol. Chem. 279 (2004) 45257-45265
56. Liu Z., Hergenhahn M., Schmeiser H.H., Wogan G.N., Hong A., and Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2963-2968
57. Li Y., Liu Z., Guo X., Shu J., Chen Z., and Li L. Aristolochic acid I-induced DNA damage and cell cycle arrest in renal tubular epithelial cells in vitro. Arch. Toxicol. 80 (2006) 524-532
58. Lord G.M., Cook T., Arlt V.M., Schmeiser H.H., Williams G., and Pusey C.D. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358 (2001) 1515-1516
59. Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., and Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43 (2004) e11-e17
60. McDermott U., Longley D.B., Galligan L., Allen W., Wilson T., and Johnston P.G. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 65 (2005) 8951-8960
61. Mei N., Arlt V.M., Phillips D.H., Heflich R.H., and Chen T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res. 602 (2006) 83-91
62. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 41 (2005) 2449-2461
63. Neumar R.W., Xu Y.A., Gada H., Guttmann R.P., and Siman R. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem. 278 (2003) 14162-14167
64. Nilsson J.A., and Cleveland J.L. Myc pathways provoking cell suicide and cancer. Oncogene 22 (2003) 9007-9021
65. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., and Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). New Engl. J. Med. 342 (2000) 1686-1692
66. Ohtsuka T., Jensen M.R., Kim H.G., Kim K.T., and Lee S.W. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene 23 (2004) 5405-5408
67. Okada H., Watanabe Y., Inoue T., Kobayashi T., Kanno Y., Shiota G., Nakamura T., Sugaya T., Fukamizu A., and Suzuki H. Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity. Nephrol. Dial. Transplant. 18 (2003) 2515-2523
68. Park W.Y., Hwang C.I., Im C.N., Kang M.J., Woo J.H., Kim J.H., Kim Y.S., Kim J.H., Kim H., Kim K.A., Yu H.J., Lee S.J., Lee Y.S., and Seo J.S. Identification of radiation-specific responses from gene expression profile. Oncogene 21 (2002) 8521-8528
69. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutat. 28 (2007) 622-629
70. Phillips D.H., and Arlt V.M. The 32P-postlabeling assay for DNA adducts. Nat. Protoc. 2 (2007) 2772-2781
71. Pineiro D., Martin M.E., Guerra N., Salinas M., and Gonzalez V.M. Calpain inhibition stimulates caspase-dependent apoptosis induced by taxol in NIH3T3 cells. Exp. Cell Res. 313 (2007) 369-379
72. Pozdzik A.A., Salmon I.J., Debelle F.D., Decaestecker C., Van den Branden C., Verbeelen D., Deschodt-Lanckman M.M., Vanherweghem J.L., and Nortier J.L. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kid. Int. 73 (2008) 595-607
73. Preitner N., Damiola F., Lopez-Molina L., Zakany J., Duboule D., Albrecht U., and Schibler U. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 110 (2002) 251-260
74. Qi X., Cai Y., Gong L., Liu L., Chen F., Xiao Y., Wu X., Li Y., Xue X., and Ren J. Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid. Toxicol. Appl. Pharmacol. 222 (2007) 105-110
75. Ricordy R., Gensabella G., Cacci E., and Augusti-Tocco G. Impairment of cell cycle progression by aflatoxin B1 in human cell lines. Mutagenesis 17 (2002) 241-249
76. Ritter B., Philie J., Girard M., Tung E.C., Blondeau F., and McPherson P.S. Identification of a family of endocytic proteins that define a new alpha-adaptin ear-binding motif. EMBO Rep. 4 (2003) 1089-1095
77. Roos W.P., and Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 12 (2006) 440-450
78. Schmeiser H.H., Janssen J.W., Lyons J., Scherf H.R., Pfau W., Buchmann A., Bartram C.R., and Wiessler M. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50 (1990) 5464-5469
79. Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele de Strihou C., and Cosyns J.P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56 (1996) 2025-2028
80. Schulz W.A. Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer 119 (2006) 1513-1518
81. Schulz W.A., Jankevicius F., Gerharz C.D., Kushima M., van Roeyen C., Bultel H., Gobell P., and Schmitz-Drager B.J. Predictive value of molecular alterations for the prognosis of urothelial carcinoma. Cancer Detect. Prev. 22 (1998) 422-429
82. Schwerdtle T., Walter I., Mackiw I., and Hartwig A. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 24 (2003) 967-974
83. Staib F., Robles A.I., Varticovski L., Wang X.W., Zeeberg B.R., Sirotin M., Zhurkin V.B., Hofseth L.J., Hussain S.P., Weinstein J.N., Galle P.R., and Harris C.C. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 65 (2005) 10255-10264
84. Stein G.S., van Wijnen A.J., Stein J.L., Lian J.B., Montecino M., Zaidi S.K., and Braastad C. An architectural perspective of cell-cycle control at the G1/S phase cell-cycle transition. J. Cell. Phys. 209 (2006) 706-710
85. Stemmer K., Ellinger-Ziegelbauer H., Ahr H.J., and Dietrich D.R. Carcinogen specific gene expression profiles in short-term treated Eker and wild type rats indicative for pathways involved in renal tumourigenesis. Cancer Res. 67 (2007) 4052-4068
86. Stiborova M., Fernando R.C., Schmeiser H.H., Frei E., Pfau W., and Wiessler M. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15 (1994) 1187-1192
87. Stiborova M., Frei E., Hodek P., Wiessler M., and Schmeiser H.H. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113 (2005) 189-197
88. Stiborova M., Frei E., Arlt V.M., and Schmeiser H.H. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 658 (2008) 55-67
89. Tchou J., Kasai H., Shibutani S., Chung M.H., Laval J., Grollman A.P., and Nishimura S. 8-oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 4690-4694
90. Vanherweghem J.L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., Richard C., Vandervelde D., Verbeelen D., Vanhaelen-Fastre R., et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341 (1993) 387-391
91. Vikhanskaya F., Lee M.K., Mazzoletti M., Broggini M., and Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res. 35 (2007) 2093-2104
92. vom Brocke J., Schmeiser H.H., Reinbold M., and Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27 (2006) 2141-2147
93. Wheeler A.P., and Ridley A.J. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. 301 (2004) 43-49
94. Williams T.M., and Lisanti M.P. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. 288 (2005) C494-C506
95. Wu K.M., Farrelly J.G., Upton R., and Chen J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): Lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 14 (2007) 273-279